Skip to content

Efficacy Evaluation of Pulmonary Daoyin Rehabilitation Techniques in the Treatment of Chronic Obstructive Pulmonary Disease in Stable Stage

Efficacy Evaluation of Pulmonary Daoyin Rehabilitation in the Treatment of Chronic Obstructive Pulmonary Disease in Stable Stage

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079435
Enrollment
Unknown
Registered
2024-01-03
Start date
2024-01-20
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable phase of chronic obstructive pulmonary disease

Interventions

Pulmonary Daoyin Rehabilitation group:After recruitment into the group, pulmonary Daoyin rehabilitatio training was given on the basis of conventional Western medical treatment and health education.
Athletic Training group:After recruitment into the group, power treadmill training was given on the basis of conventional western medical treatment and health education.

Sponsors

The First Affiliated Hospital of Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Clear diagnosis of Patients with stable COPD; (2) Age between 40 and 80 years; (3) Not participating in another clinical study within 1 month prior to enrollment; (4) Voluntarily accepting treatment and signing an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those who were not able to cooperate in completing pulmonary function tests, exercise cardiopulmonary tests, and 6-minute walk tests; (2) Those with resting oxygen saturation <90% (without oxygen); (3) Pregnant patients; (4) Patients with various psychiatric disorders such as learning cognitive ability and listening, reading and writing disorders, and delirium; (5) Previous history of syncope; (6) Combined bronchial asthma, bronchiectasis, interstitial lung disease, active tuberculosis, advanced tumors, entrapment aneurysm, lower limb thrombosis; (7) Combination of massive pneumothorax, massive pleural effusion, acute pulmonary embolism, neuromuscular disease, and osteoarthropathy affecting respiratory and motor functions; (8) Combined with unstable angina pectoris, patients with acute myocardial infarction, uncontrolled malignant arrhythmia, acute endocarditis, acute myocarditis or pericarditis, symptomatic severe aortic valve stenosis, and cardiac function grade 2 or above; (9) Those with combination of severe liver and kidney diseases (severe liver diseases are cirrhosis, portal hypertension and variceal bleeding, and severe kidney diseases include those requiring dialysis and kidney transplantation).

Design outcomes

Primary

MeasureTime frame
6-min Walking Distance;Cardiopulmonary Exercise Test;liver function;

Secondary

MeasureTime frame
Times of Acute Exacerbation;Pulmonary Function;modified Medical Research Council;Clinical COPD Questionnaire;Saint George Respiratory Questionnaire;modified COPD - Patient Reported Outcomes;modified Efficacy Satisfaction Questionnaire - COPD;

Countries

China

Contacts

Public ContactZhang Hailong

The First Affiliated Hospital of Henan University of Chinese Medicine

zhanghailong6@126.com+86 136 4371 8969

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026